Irrespectively of these limitations, our HPLC analysis shows a significant effect of SMN protein upregulation in inducing a significant and selective enhancement of NE levels in the CSF of severe SMA patients, thus highlighting a disease severity-specific neurochemical effect of Nusinersen treatment. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.